Print Friendly Page

Protocol No. NSABPB55

Phase III

Age Group Adult

Scope National

Sponsor Type National

Title A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo Versus Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Applicable Disease Sites Breast

Drugs Involved AZD2281 (Olaparib); Lynparza (Olaparib); MK-7339 (Olaparib); Olaparib; placebo

Status Open (affiliates only)

Participating Institutions Swedish American Hospital, Rockford